To estimate the prevalence of dyslipidemia (DLP) among individuals with idiopathic granuloma annulare and to examine associations with disease characteristics and comorbidities, such as metabolic syndrome.
G
RANULOMA ANNULARE (GA) is a benign, usually self-limited, granulomatous skin disease of unknown etiopathogenesis. The characteristic eruption manifests as flesh-colored to erythematous or purple papules with a tendency toward annular grouping and a potential to involve any area of the skin. [1] [2] [3] The generalized form of the disease shows a more chronic, relapsing course; a later age of onset; rare spontaneous resolution; and poorer response to therapy compared with the localized form. 1 Many precipitating factors have been reported, and various hypotheses as to the etiopathogenesis of GA have been put forward 1, 2 ; however, little is known about the initial triggers and associated comorbidities. Associations with systemic disease have been described but not consistently corroborated. [3] [4] [5] [6] An association with diabetes mellitus 1, 6 has been debated. 7 The prevalence of other comorbidities, such as hypertension, obesity, and thyroid, cardiovascular, and malignant disease, has not been systematically investigated. Data from uncontrolled studies 1, 3 and case series 8 have not been validated by large-scale controlled studies.
Co-occurrence of GA with necrobiosis lipoidica diabeticorum has been reported, [9] [10] [11] especially in patients with diabetes mellitus, and these diseases share certain histopathologic features, including lipid deposition. 10, 12 Similarly, several cases of eruptive xanthoma associated with hypertriglyceridemia showed GA-like histopathologic characteristics. 13, 14 Interestingly, the T-cell repertoire (CD4 ϩ T cells, helper T cell subtype 1 profile)/cytokine pattern (tu-mor necrosis factor [TNF] , interferon ␥, interleukin 2 , and IL-4) in GA 15, 16 is similar to that of skin diseases that have been associated with dyslipidemia (DLP), such as lichen planus and psoriasis 17, 18 ; psoriasis also has been associated with metabolic syndrome. 18 Sarcoidosis is another granulomatous process that shows a similar cytokine pattern 19, 20 and has been associated with low levels of high-density lipoprotein cholesterol (HDL-C) and hypertriglyceridemia. 21 Chronic inflammation in these diseases could explain the link with DLP. 22 Interestingly, an uncontrolled study of 100 patients with generalized GA by Dabski and Winkelmann 3 reported percentages of hypercholesterolemia (19.6%) and hypertriglyceridemia (23.3%) in patients with documented lipid values. The study showed a higher prevalence of elevated serum lipid levels in the annular rather than nonannular GA subgroups. However, the study did not include the reference range for the lipid values and measurements of lowdensity lipoprotein cholesterol (LDL-C) and HDL-C levels, which would have allowed for a determination of DLP prevalence as well as comparison with subsequent studies. To our knowledge, no other studies have investigated the association between GA and components of DLP. In the past 15 years, there have been no studies on comorbidities in GA or clinical studies relevant to the etiology of the disease.
This lack of information prompted us to investigate the prevalence of DLP, metabolic syndrome, and other comorbidities (eg, hypertension, type 2 diabetes mellitus, and hypothyroidism) in patients with idiopathic GA. We also investigated whether an association exists between clinicopathologic features of GA (extent, morphologic characteristics, and histopathologic type) and DLP or other comorbidities.
METHODS

STUDY POPULATION
This case-control study, consisting of a medical record review (from 2002 to 2010), was conducted at Rhode Island Hospital in Providence and South Shore Medical Center, Atrius Healthcare System, in Norwell, Massachusetts. Inclusion criteria were age older than 18 years, histopathologic confirmation of diagnosis, and adequate clinical data on the skin disease, comorbidities, lipid levels, and medications. Data on age, sex, race/ethnicity, socioeconomic status, age at onset of GA, location and clinical features of skin lesions, histopathologic diagnosis, lipid values, comorbidities (type 2 diabetes mellitus, hypertension, hypothyroidism, obesity, and metabolic syndrome), smoking status, and use of lipidlowering medications and/or ␤-blockers were collected. Socioeconomic status was approximated by medical insurance status (scale of 1-3, with 1 being the lowest and 3 the highest). Lesions were characterized as localized, disseminated (Ͼ10 lesions), or generalized (involving the trunk and upper or lower extremities), as previously defined. 23 Annular GA lesions were composed of individual coalescing papules arranged in a ringlike or circinate configuration. 3 In accordance with previous studies, 3 cases with predominantly annular GA lesions were classified in the annular subgroup. A thorough search revealed 140 cases with complete historic and clinical/laboratory data that were selected from a pool of 400 patients; 420 individuals serving as controls, with a ratio to cases of 3:1, were selected from a pool of 4000. Controls were selected from primary care clinics at Rhode Island Hospital and South Shore Medical Center and were confirmed to not have a history of GA and skin diseases associated with hyperlipidemia, such as necrobiosis lipoidica. The records of patients serving as controls were matched to cases on the following variables: age, sex, race/ethnicity, type 2 diabetes mellitus, hypothyroidism, and hypertension. Furthermore, controls closely approximated cases in demographics and socioeconomic status. The study was approved by the Lifespan institutional review board, the major teaching hospitals affiliated with the Warren Alpert Medical School of Brown University.
DEFINITION OF COMORBIDITIES
Hypertension was defined as blood pressure of 130/85 mm Hg or higher and obesity as a body mass index higher than 30 (calculated as weight in kilograms divided by height in meters squared). Hypothyroidism was defined as overt disease validated by elevated (Ͼ5.0 mIU/L) thyroid-stimulating hormone and low (Ͻ0.8 ng/dL; to convert to picomoles per liter, multiply by 12.871) free thyroxine levels and/or active pharmacologic treatment. Type 2 diabetes mellitus was defined as recurrent or persistent hyperglycemia diagnosed by demonstrating any one of the following: fasting plasma glucose level, 126 mg/dL or more (to convert to millimoles per liter, multiply by 0.0555); plasma glucose level, 200 mg/dL or more, 2 hours after a 75-g oral glucose ingestion as in a glucose tolerance test; symptoms of hyperglycemia and random plasma glucose level, 200 mg/dL or more; and hemoglobin A 1c concentration, 6.5% or more (to convert to proportion of total hemoglobin, multiply by 0.01). 24 Metabolic syndrome was defined by the criteria of the International Diabetes Federation. 25 The definition includes central obesity (defined as a waist circumference with ethnicity-specific values or body mass index Ͼ30) and any 2 of the following: elevated triglyceride concentration (Ͼ150 mg/dL; to convert to millimoles per liter, multiply by 0.0113) or specific treatment for this lipid abnormality, reduced HDL-C level (Ͻ40 mg/dL in men and Ͻ50 mg/dL in women; to convert to millimoles per liter, multiply by 0.0259) or specific treatment for this lipid abnormality, elevated blood pressure (systolic Ն130 mm Hg and/or diastolic Ն85 mm Hg) or treatment of previously diagnosed hypertension, and elevated fasting plasma glucose level (Ն100 mg/dL) or previously diagnosed type 2 diabetes.
ASSESSMENT OF LABORATORY FINDINGS
Histopathologic subtypes of GA included palisaded, interstitial, mixed (palisaded and interstitial), and deep. Cases with histopathologic characteristics suggestive of a granulomatous drug reaction 26 and those showing histopathologic features associated with systemic disease (active vasculopathy, especially in the setting of an atypical clinical presentation) 4 were excluded from the study. The age of the control at the time lipid values were determined was matched to that of the patient at the onset of disease. If a patient or control was receiving a lipidlowering medication, such as a statin or fibrate, the lipid values obtained before the medication was started were reported. Hypercholesterolemia was diagnosed when the total cholesterol level was higher than 200 mg/dL (to convert to millimoles per liter, multiply by 0.0259) and hypertriglyceridemia when the triglyceride concentration was higher than 150 mg/ dL. Low levels of HDL-C were diagnosed as 40 mg/dL and high levels of LDL-C were diagnosed when higher than 130 mg/dL. Dyslipidemia was defined as the presence of 1 or more of its associated components: hypercholesterolemia, elevated LDL-C, low HDL-C, and hypertriglyceridemia.
STATISTICAL ANALYSIS
Descriptive frequencies, means, and medians were used to describe the study and control populations. The proportions of patients with DLP were compared between cases and controls by univariate analyses, using 2 tests to compare categorical variables between the groups and unpaired t tests for comparison of continuous variables. The median values of the groups were compared with the Mann-Whitney test. Analysis of variance testing was used when a variable had 3 or more groups. All P values are 2-sided, and significance was assessed at PՅ.05. Given the binary nature of the dependent variable, we used multivariate logistic regression with robust standard errors to examine the association between GA and DLP. The model was adjusted for potential confounders, including age and sex, in addition to cardiovascular risk factors (obesity, metabolic syndrome, and smoking). 27 Use of ␤-blockers was also adjusted for because the earlier generation of this class, nonvasodilating ␤-blockers, may cause DLP. 28 Independent variables were chosen based on previous studies. 27, 29 Adjusted odds ratios (ORs) with 95% CIs and P values were calculated. Lipid levels and age were analyzed as continuous variables. Multicollinearity between independent variables was assessed using the variation inflation factor. All statistical analyses were performed using commercial software (Stata/SE, version 10; StataCorp).
RESULTS
HIGH PREVALENCE OF DLP IN GA
The study included 140 patients with GA (age, 19-81 years) and 420 controls (age, 18-84 years) ( Table 1) . The female to male ratio (2.8) was in accordance with previous studies. 1 Controls were matched for age, sex, race/ethnicity, type 2 diabetes mellitus, hypothyroidism, and hypertension. Dyslipidemia was diagnosed in 79.3% of the patients compared with 51.9% of the controls (P Ͻ .001). Statistically significant differences between the patient and control groups were shown for total cholesterol, triglycerides, and LDL-C (PϽ.001 for all variables). The breakdown of patients with 1, 2, 3, or 4 components of DLP was 25.2%, 43.2%, 21.6%, and 9.9%, respectively. The respective percentages for controls were 37.6%, 42.2%, 14.7%, and 5.5%.
CLINICAL AND HISTOPATHOLOGIC FEATURES OF GA CASES
The prevalence of generalized GA was 16.4%, which is between that reported by Dabski and Winkelmann (9.5%) 3 and that reported by Studer et al (25%). 1 The distribution of lesions was in accord with previous studies. 1 The upper extremity was the most common site involved (67.1%), followed by the lower extremity (50.7%) ( Table 2 ). The lower extremity was more involved in disseminated/generalized than in localized GA (P Ͻ .001). The annular morphologic characteristics were less common in generalized than localized/ disseminated GA, but the difference did not reach statistical significance. Palisaded was the most common histopathologic type. There was no association between histopathologic type and GA morphologic characteristics. 
LIPID ABNORMALITIES IN GA SUBGROUPS
A statistically significant association resulted between the extent of GA and DLP (P=.02), with generalized GA showing a higher prevalence of DLP than the disseminated and localized subgroups (100% vs 71.4% and 77.3%) ( Table 3 ). In addition, annular GA morphology was associated with hypercholesterolemia (P = .02) and DLP (P=.01). Clinical subgroups were not significantly correlated with any other comorbidities. There were no associations between the histopathologic type and lipid abnormalities or other comorbidities.
ADJUSTMENT FOR CONFOUNDING VARIABLES AND ODDS RATIO
Results of multivariate logistic regression are shown in Table 4 . The regression model demonstrated that GA was associated with DLP (OR, 4.04; 95% CI, 2.53-6.46), even after controlling for confounders, including age, sex, smoking, obesity, metabolic syndrome, and ␤-blocker use.
COMMENT
The present study showed an association between GA and DLP. After controlling for confounding variables, patients with GA had 4 times the odds of developing DLP compared with the controls. The study also revealed statistically significant quantitative differences for total cholesterol, triglycerides, and LDL-C between the GA and control groups. Generalized GA showed a higher prevalence of DLP than did the localized and disseminated subgroups, and the annular lesion morphology was associated with hypercholesterolemia and DLP. Although associations of GA with systemic disease have been reported, 1,4-6 comorbidities have not been systematically investigated. Preliminary observations that support an association between GA and DLP include cooccurrence with necrobiosis lipoidica, 9-11 microdroplet lipid staining in GA (45.5% of generalized and 37.5% of localized), 12 and sharing histopathologic features with disorders associated with DLP, such as necrobiosis lipoidica 9, 10 and eruptive xanthoma. 13, 14 The study by Dabski and Winkelmann 12 showed that microdroplet lipid staining was positive in 80% of annular and 39.3% of nonannular GA cases, and this observation is consistent with the results of our study, which showed an increased prevalence of DLP and hypercholesterolemia in annular vs nonannular GA subgroups. The lipid staining in the study 12 was seen only inside the histiocytes (ie, not outside the cellular aggregates of the granuloma). Interestingly, other granulomatous processes, such as the granulomatous variant of chronic pigmented purpuric dermatosis, have been associated with hypercholesterolemia. 30 , 31 The lesions in cases of granulomatous pigmented purpuric dermatosis were clinically similar to those of GA, and it was suggested that an inflammatory reaction of microvasculature induced by microdroplets or microdeposits associated with hyperlipidemia may trigger a granulomatous dermatosis. 31 The association of GA with DLP may be related to the inflammation caused by the disease. Inflammation plays an important role in the development of DLP, 32, 33 and chronic inflammation in diseases with cytokine patterns similar to that of GA, such as lichen planus and psoriasis, 17 ,18 may trigger DLP. 22 Treatment of DLP has been associated with a clinical improvement in psoriasis, 34 and TNF inhibitors, which are helpful in psoriasis, have been associated with a beneficial increase in HDL-C level 35 or decrease in serum triglycerides concentration. 36 Tumor necrosis factor has been associated with the maintenance stage of granulomatous processes such as GA, 37 and GA has been treated with TNF inhibitors, 38,39 which may Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. SI conversion factors: to convert cholesterol and triglyceride values to millimoles per liter, multiply by 0.0259 and 0.0113, respectively. a Significant P values are shown in boldface. The first P value column indicates differences between the annular and nonannular groups, and the second column indicates differences among the localized, disseminated, and generalized groups. be attributed not only to downregulation of the helper T-cell subtype 1 cytokine pattern but also improvement of DLP. Nonetheless, GA onset has been associated with TNF inhibitor treatment (uncontrolled), 40 possibly via autoimmune mechanisms.
On the other hand, a granulomatous process may be secondary to promotion of inflammation and/or microvascular dysfunction, including decreased skin blood flowmotion, 41 as a result of hypercholesterolemia. 42 Although microangiopathy has been reported in GA, 43 microvascular function has not been studied. Still, the microangiopathy in GA has been considered similar to that observed in necrobiosis lipoidica and diabetes, with high ␤-glucuronidase levels possibly as a defense mechanism involved in the degradation of mucopolysaccharides and glycoproteins around blood vessels. 44 This concept is supported by the histopathologic finding of thick, multilayered, hyalinized basal lamina around capillaries in GA, which was most prominent in the generalized form. 45 Increased levels of oxidized LDL-C have been shown in psoriasis lesions 46 and were associated with the immune inflammatory events that result in progressive skin damage. Interestingly, oxidized LDL-C has been shown to increase IL-2 receptors in T cells, 47 and IL-2 is dramatically increased in GA. 15 Therefore, it needs to be investigated whether oxidized LDL-C-mediated tissue damage can be involved in the pathogenesis of GA.
Our study has strengths and limitations. To our knowledge, this is the largest study on patients with wellcharacterized GA and the first to include adequate documentation of lipid abnormalities. To minimize selection biases, we included patients from both hospital and community environments. Furthermore, the distribution of potentially confounding factors, such as age, sex, obesity, type 2 diabetes mellitus, hypothyroidism, and hypertension, was homogeneous in the GA and control groups. Drug therapy (ie, ␤-blockers) could not have biased the results because it was balanced between the 2 groups. A possible limitation is that socioeconomic status was approximated based on insurance data and did not include data on educational level and annual income. Furthermore, we documented smoking status as current or never and therefore could not determine whether history of smoking could have introduced potential confounding. Similarly, the effects of other lifestyle factors, such as exercise and alcohol use, were not measured, although other included variables (ie, low level of exercise is associated with obesity, and excessive alcohol use is associated with obesity, metabolic syndrome, diabetes, and hypertension) 48 may partially account for these factors.
The results of our study have important clinical consequences. First, a diagnosis of GA warrants an evaluation for possible co-occurrence of DLP. Because of its serious complications, DLP should be considered a more severe comorbidity than GA and warrants prompt management. Furthermore, the presence of generalized GA and/or annular lesion morphology should trigger a high index of suspicion for DLP. Finally, the close relationship with DLP may be relevant when defining management options for refractory GA, such as chronic generalized GA. In this case, combined treatment options, including lipid-lowering medications and/or TNF inhibitors, may be beneficial.
In conclusion, this study indicates an association between GA and DLP. Generalized GA shows a significantly higher prevalence of DLP than the disseminated and localized subgroups, and annular lesion morphology is associated with hypercholesterolemia and DLP in this study. Clinicians should be aware of these associations and consider them in the management of GA. Additional studies are needed to validate that GA can serve as a new marker for DLP. 
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Testing Lipid Levels in Granuloma Annulare I n this issue, Wu et al 1 report a 79.3% prevalence of dyslipidemia (DLP) among adults with granuloma annulare (GA) compared with a 51.9% prevalence of DLP in controls matched for age, sex, race/ethnicity, and presence of type 2 diabetes mellitus, hypothyroidism, and hypertension (P Ͻ.001). Although the cause of GA is unknown, 2 the finding of DLP among so many patients comes as a surprise. Heretofore, only vague hints suggested a possible association with a lipid abnormality. Patients with generalized GA occasionally have an abnormality of glucose metabolism, microangiopathy, and microdroplet lipid deposits inside histiocytes.
Most dermatologists do not subject patients with GA to laboratory testing. The cause of GA is unknown, and a search for provoking factors is thereby futile. Many patients are in otherwise excellent health, including children.
Failure to test for fasting serum lipid levels in patients with GA may be a practice gap. Although large
